


# Tividenofusp Alfa Treatment in a Male Sibling Pair with Non-Neuronopathic Mucopolysaccharidosis Type II

Irene J Chang, Jacqueline Madden, Annie Sako, Jill Dwyer, Daniel Fertek, Adam Scheller, Sharon O'Byrne, Imanol Zubizarreta Arambarri, Peter Chin, Paul Harmatz

Figure S1. Phase 1/2 study design



<sup>a</sup>Last time point with available study data for these patients (October 2024 interim data cut).

From *New Engl J Med*, Muenzer J *et al.*, An Intravenous Brain-Penetrant Enzyme Therapy for Mucopolysaccharidosis II, Vol. 394, pp. 39–50. Copyright © 2026 Massachusetts Medical Society. Reprinted with permission from Massachusetts Medical Society. Appears as Figure 1A in the original article.

## ABBREVIATIONS

6MWT, 6-minute walk test; CSF, cerebrospinal fluid; DS, dermatan sulfate; HS, heparan sulfate; JROM, joint range of motion; KABC-II, Kaufman Assessment Battery for Children, Second Edition; NfL, neurofilament light chain.

Tividenofusp alfa has not been approved by any Health Authority outside the United States. Denali Therapeutics Inc. All rights reserved 2026.

Supplement to poster presented at the 46th SIMD Annual Meeting, May 17–20, 2026, Rio Grande, Puerto Rico